Overview

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.

Phase:

Phase 3

Details

Lead Sponsor:

Vanda Pharmaceuticals